Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington’s disease

[1]  Jaime Kulisevsky,et al.  Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters , 2019, Clinical nuclear medicine.

[2]  R. Roos,et al.  Structural and functional changes of the visual cortex in early Huntington's disease , 2018, Human brain mapping.

[3]  J. Kulisevsky,et al.  Structural and metabolic brain correlates of apathy in Huntington's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[4]  Kat Arney.  Improved metrics for Huntington’s disease trials , 2018, Nature.

[5]  C. Kawanishi,et al.  Effect of Memantine on Brain Metabolic Activity and Perfusion in Drug-naïve Moderate Alzheimer’s DiseasePatients , 2018 .

[6]  Sarah J Tabrizi,et al.  Structural imaging in premanifest and manifest Huntington disease. , 2017, Handbook of clinical neurology.

[7]  J. Kulisevsky,et al.  Striatal hypometabolism in premanifest and manifest Huntington’s disease patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  C. Frost,et al.  Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington’s Disease , 2016, Journal of the International Neuropsychological Society.

[9]  Ciprian Catana,et al.  Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging , 2016, NeuroImage.

[10]  J. Kulisevsky,et al.  Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. , 2016, Parkinsonism & related disorders.

[11]  F. Niccolini,et al.  Current status of PET imaging in Huntington’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Julie C. Stout,et al.  The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease , 2015, Neuropsychologia.

[13]  Bruce R. Rosen,et al.  Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data , 2014, NeuroImage.

[14]  Chris Frost,et al.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data , 2012, The Lancet Neurology.

[15]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[16]  Hans J. Johnson,et al.  Cerebral cortex structure in prodromal Huntington disease , 2010, Neurobiology of Disease.

[17]  Koen Van Laere,et al.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[19]  G. Small,et al.  Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[20]  R. Roos,et al.  Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. , 2008, General hospital psychiatry.

[21]  S. Folstein,et al.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study , 1992, Neuroradiology.

[22]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[23]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.